Septerna, Inc. (SEPN)

Septerna's stock experienced a 302.42% increase from March 31, 2025, to March 30, 2026. In November 2025, Septerna highlighted pipeline progress and reported its third-quarter financial results, including the selection of SEP-479 and initiation of a Phase 1 trial for SEP-631. In March 2026, positive Phase 1 data for SEP-631 were announced, with plans for Phase 2b development. Several analyst firms initiated coverage or increased price targets in March 2026. The company reported its fourth-quarter and full-year 2025 financial results, highlighting a strong cash position. The discontinuation of the SEP-786 Phase 1 clinical trial due to safety concerns was reported in March 2025.

Demand seasonality is not a relevant factor for Septerna, Inc. Demand for its drug candidates is driven by clinical trial progress, regulatory approvals, and medical need, rather than seasonal fluctuations.

Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel oral small molecule medicines that target G protein-coupled receptors (GPCRs). The company uses its Native Complex Platform to develop GPCR therapies for unmet medical needs, focusing on endocrinology, immunology and inflammation, and metabolic diseases. Key programs include SEP-786 (later discontinued) and SEP-479 for hypoparathyroidism, SEP-631 for chronic spontaneous urticaria, a TSHR program for Graves' disease and thyroid eye disease, and incretin receptor agonists for metabolic disorders. Septerna also has a collaboration with Novo Nordisk for metabolic-related diseases.

Septerna, Inc. is headquartered in South San Francisco, California, United States. The company has a global collaboration with Novo Nordisk, but further details about its operational or market geographic footprint are not available.

Septerna's brand reputation appears positive, driven by pipeline advancements and strong financial performance. The company has received favorable analyst ratings, with 100% "Buy" recommendations from 6 ratings within the last six months. News releases highlight pipeline progress, positive clinical trial data for SEP-631, and a robust financial position. While the discontinuation of the SEP-786 Phase 1 clinical trial was a setback, the company has advanced SEP-479 as a next-generation candidate.

Septerna, Inc. has significant institutional ownership, with 124 institutional owners and shareholders holding 39,333,643 shares as of March 31, 2026, accounting for approximately 100.1% of the 1000 largest holdings, with a geographical origin of 95.7% from the United States. Individual ownership stands at about 3.21%. Major institutional owners include Ra Capital Management, L.p., Driehaus Capital Management Llc, TRV Gp Vi, Llc, Samsara BioCapital, LLC, Goldman Sachs Group Inc, Siren, L.L.C., BlackRock, Inc., Bvf Inc/il, Vanguard Group Inc and Avoro Capital Advisors LLC.